Radiopharm Theranostics Limited - Sponsored ADR RADX

Radiopharm Theranostics earns late-breaking oral presentation slot at 2026 Society of Neuro-Oncology Annual Meeting to report positive interim data from U.S. Phase 2b imaging trial of RAD101. Positive Phase 2b RAD101 data at major neuro-oncology conference drives significant investor interest and advances clinical positioning.

Radiopharm Theranostics announces positive data from Phase 1 imaging trial of RAD301 in pancreatic ductal adenocarcinoma patients. Positive Phase 1 trial results for RAD301 signal moderate advancement in pipeline development.

Radiopharm Theranostics dosed first patient in second cohort of Phase 1/2a trial for BetaBart (RV-01) targeting B7-H3 expressing solid tumors. Early-stage trial milestone advances pipeline but lacks immediate commercial or revenue effects.

Radiopharm Theranostics advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial after positive recommendation from Data Safety and Monitoring Committee. Positive DSMC recommendation enabling next trial cohort marks key development milestone for RAD202 radiopharmaceutical candidate.

Radiopharm Theranostics will meet with the U.S. FDA to align on pivotal Phase 3 trial design for RAD 101 in diagnosis of brain metastases. FDA alignment advances RAD 101 toward Phase 3 trial and potential regulatory progress for brain metastases diagnosis.

Radiopharm Theranostics announces RAD101 topline results alongside FY26 cash flow projections. RAD101 topline data and FY26 cash flows directly affect clinical pipeline valuation and funding outlook.

Radiopharm Theranostics provided a business update on pipeline progress, clinical trials, partnerships and funding plans for its radiopharmaceutical oncology programs. Business updates on trials and partnerships can moderately shift near-term sentiment and operational outlook without guaranteeing fundamental change.

Radiopharm Theranostics announces concurrent US$4.1 million registered direct offering and up to A$12.7 million Australian placement and share purchase plan. Capital raise secures operational funding but triggers share dilution with moderate effect on stock trajectory.

Radiopharm Theranostics achieves confirmed durable partial response in ongoing Phase 1 trial of RAD204 in advanced solid tumors post-immunotherapy. Positive Phase 1 data for RAD204 signals major pipeline progress that can shift company trajectory and sentiment.

Radiopharm Theranostics announces positive Phase 2b trial results of RAD 101 for diagnosis of brain metastases. Positive Phase 2b results for RAD 101 advance diagnostic product development and strengthen company growth prospects.

Radiopharm Theranostics Limited (RADX) released its Fiscal 3Q:26 Cash Flow Report detailing cash inflows, outflows, and net position. Fiscal 3Q:26 cash flow report impacts RADX's financial health and investor views on liquidity.

Radiopharm Theranostics showcases Phase 1 pipeline progress and anticipates RAD 101 data readout in June, to be presented at Deutsche Bank Conference. Pipeline highlights and impending Phase 1 RAD 101 data could moderately influence investor sentiment and early-stage development trajectory.

Radiopharm Theranostics ADR (RADX) details its clinical pipeline of radiopharmaceuticals for oncology, including RAD204 for prostate cancer imaging, RAD301 for lung cancer therapy, and other programs in early clinical stages targeting solid tumors. Clinical programs overview showcases RADX's innovative theranostics pipeline, likely boosting investor sentiment and influencing market performance amid biotech sector interest.

Radiopharm Theranostics issued a business update highlighting pipeline advancements, including positive preclinical results for lead candidates, new preclinical data, planned clinical trials, cash position, and upcoming milestones. Pipeline progress and milestones signal moderate potential for improved clinical outcomes and investor interest without transformative shifts.

Radiopharm Theranostics presented initial findings from the Phase 1 first-in-human HEAT clinical trial of 177Lu-RAD202 for HER2+ solid tumors at the American Association for Cancer Research 2026. Initial Phase 1 data from first-in-human trial of novel HER2-targeted theranostic at major oncology conference marks key milestone likely to boost investor sentiment and valuation.

Radiopharm Theranostics completed patient enrollment in its U.S. Phase 2b imaging trial of RAD 101, a novel PET imaging agent designed to improve diagnosis of brain metastases from solid tumors. Completing Phase 2b enrollment advances RAD 101 toward data readout and potential approval, significantly boosting RADX's clinical pipeline and investor sentiment.

Radiopharm Theranostics advances to Cohort 3 in the Phase 1 dose-escalating clinical trial of 177Lu-RAD202, indicating positive safety and tolerability data from prior cohorts. Advancing to Cohort 3 in Phase 1 trial signals promising early safety profile for 177Lu-RAD202, moderately enhancing pipeline credibility and short-term market sentiment.

Radiopharm Theranostics and Siemens Healthineers signed a clinical supply agreement for RAD101 in the U.S., securing supply chain support for its phase 2a glioblastoma trial via Siemens' extensive nuclear medicine network. Partnership with Siemens Healthineers for RAD101 clinical supply advances U.S. trial execution and strengthens Radiopharm's theranostics pipeline credibility.

Radiopharm Theranostics (RADX) released interim analysis for RAD 101 Phase IIb trial. Phase IIb interim analysis of lead candidate RAD 101 represents a major clinical milestone that could significantly impact RADX's development pipeline and stock performance.

Radiopharm Theranostics dosed the first patient in its Phase 1 clinical study of RAD 402, a targeted alpha therapy for advanced prostate cancer. First-patient dosing in Phase 1 trial of RAD 402 marks a major pipeline advancement for prostate cancer, likely boosting investor sentiment and stock performance significantly.

Radiopharm Theranostics dosed the first patient in a Phase 1 clinical trial for RAD 402, advancing the radiopharmaceutical into the clinic. Dosing the first patient in Phase 1 for RAD 402 represents a major pipeline milestone that could significantly boost investor sentiment and stock trajectory.

Radiopharm Theranostics' RAD101 achieved primary endpoint in 90% of patients in Phase IIb trial for brain metastases. RAD101's 90% primary endpoint success in Phase IIb brain metastases trial fundamentally transforms Radiopharm's pipeline value and investor outlook.

Radiopharm Theranostics announced 90% positive interim data for its RAD101 trial and plans Phase III discussions with the FDA. 90% positive RAD101 interim data enables Phase III FDA talks, marking a major clinical milestone that could drive stock performance and pipeline advancement.

Radiopharm Theranostics achieved primary endpoint in 90% of patients at second interim analysis of RAD 101 Phase 2b imaging trial for brain metastases. Strong Phase 2b interim data meeting primary endpoint in 90% of patients advances key imaging asset, likely boosting stock and pipeline prospects.

AtomVie Global Radiopharma supplied the first patient dose in Radiopharm Theranostics' Phase 1/2a clinical study of 177Lu-BetaBart (RV-01). First patient dosing in Phase 1/2a trial advances RADX's key radiopharmaceutical candidate toward potential approval, boosting market sentiment and valuation prospects.

Radiopharm Theranostics Limited dosed the first patient in its Phase 1/2a clinical study of BetaBart (RV-01), a novel radiotherapy targeting solid tumors via the CXCR4 receptor. Advancing to first-patient dosing in a Phase 1/2a trial represents a major clinical milestone that could significantly enhance investor confidence and stock valuation for the biotech firm.

Radiopharm Theranostics Limited reported its fiscal first half results, highlighting significant activity and cash flow developments. The company is focused on advancing its pipeline of radiopharmaceuticals, with ongoing clinical trials and collaborations aimed at enhancing its market position. Financial metrics indicate a strategic allocation of resources towards growth initiatives, reflecting a commitment to innovation in the theranostics sector. Significant advancements in clinical trials and strategic resource allocation are likely to impact future performance and investor sentiment.

Radiopharm Theranostics Limited reported its half-year financial results, highlighting key business updates and performance metrics. The company continues to advance its pipeline of radiopharmaceuticals, focusing on innovative therapies for cancer treatment. Financial results indicate growth in revenue and strategic initiatives aimed at enhancing market presence and operational efficiency. Management expressed optimism about future prospects and ongoing projects. The financial results and strategic updates suggest significant potential for future growth and market positioning.

Radiopharm Theranostics Limited - Sponsored ADR (RADX) is highlighted in Zacks Small Cap Research's best ideas for 2026, indicating strong potential for growth and investment interest. The company focuses on developing radiopharmaceuticals for targeted cancer therapies, which positions it well in the expanding market for precision medicine. Analysts suggest that RADX's innovative approach and strategic partnerships could enhance its competitive edge and drive future performance. RADX's focus on innovative cancer therapies and strategic partnerships is likely to significantly impact its future performance and market positioning.

Radiopharm Theranostics Limited has increased its ownership stake in Radiopharm Ventures to 87.5%. This move is part of the company's strategy to strengthen its position in the radiopharmaceutical sector, enhancing its operational control and potential for future growth. Increasing ownership in a subsidiary significantly impacts strategic positioning and future growth potential.